Renovorx closes $6.1 million private placement

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. the closing of this private placement extends renovorx's cash runway as renov.
RNXT Ratings Summary
RNXT Quant Ranking